APP13007 - Clobetasol Propionate Ophthalmic Suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery

Model: APP13007

Exhibitor: FORMOSA PHARMACEUTICALS , INC

Booth No: N/A

Characteristic

APP13007 is expected to provide ophthalmologists and patients who receive ocular surgeries with compelling, effective, and more convenient postoperative anti-inflammatory and pain relief solution.
√ Derived from Formosa Pharma’s proprietary APNT nanoparticle formulation technology.
√ Indication: Inflammation and Pain after Ocular Surgery
√ US FDA approved – the first new steroid in over 15 years on the ophthalmic market which utilizes one of the most potent corticosteroids.
√ Dosing regimen: 1 drop, twice per day for 2 weeks.
√ Low dosing frequency and short duration of treatment; no tapering needed.
√ Strong potential for additional indications, e.g., acute dry eye syndrome (DES) and allergic conjunctivitis.
√ Safety profile comparable to placebo, comfort, no foreign body sensation when instilling, and low incidence of increased intraocular pressure (IOP).
√ Our commercialization partners cover the following regions:
• North America: Canada and United States
• Asia: Mainland China, MENA, Israel, India, Malaysia, and south Asian countries
• Europe: Switzerland and Portugal
• LATAM: Brazil, Argentina, and Colombia
• Africa: Kenya, Nigeria, and South Africa